Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-11.5%
5Y CAGR+58.9%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-11.5%/yr
Annual compound
5Y CAGR
+58.9%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
10.1x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $152.77M | -57.6% |
| 2024 | $359.95M | +13.7% |
| 2023 | $316.54M | +43.5% |
| 2022 | $220.58M | +166.8% |
| 2021 | $82.69M | +449.0% |
| 2020 | $15.06M | +11.1% |
| 2019 | $13.55M | - |